LGM Pharma Expands GLP Bioanalysis and Impurity Testing Capabilities With Sannova Analytical Integration in New Jersey, US

LGM Pharma now offers new capabilities centered on a single facility. Sannova Analytical's laboratory in Somerset, New Jersey delivers three service lines that LGM Pharma did not previously provide: GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations.

With the acquisition announced on October 22, 2026, these services now sit within a company whose headquarters in Boca Raton, Florida, has built its business on API sourcing, contract analytical testing, and drug development services.

The Somerset Laboratory at the Center of the Deal

Sannova Analytical operates as a contract research organization, and its Somerset, N.J. laboratory is the asset that LGM Pharma's announcement emphasized. The announcement's subheadlines identified the facility directly as the source of the expanded capabilities, describing it as the site that adds GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations.

Two of those disciplines address requirements that sponsors and manufacturers face in regulated drug product programs. Nitrosamine impurity assessment in particular has become a prominent area of focus in pharmaceutical analytical work.

Extractables and leachables evaluations concern the identification and quantification of compounds that may migrate into a drug product from packaging or manufacturing materials. The third, GLP bioanalysis, extends LGM Pharma's portfolio into the bioanalytical side of contract research.

How the New Services Fit LGM Pharma's Existing Platform

LGM Pharma organizes its offerings around three main pillars, API products, API sourcing, and CDMO services, alongside an analytical services division. That division already included analytical testing, stability services, and analytical testing services tailored separately to compounders and to manufacturers.

The Sannova acquisition adds GLP bioanalytical work to a division whose testing was previously built around cGMP analytical services. The API sourcing division encompasses strategic sourcing, regulatory support, logistics, a manufacturer management program, and a dedicated 505(b)(2) pathway service.

The CDMO services division covers formulation development, solid dose delivery systems, liquids and suspensions, semi-solids, suppositories, commercial scale-up facilities and equipment, and regulatory management.

Following the transaction, the combined company's website directs visitors to a dedicated capabilities page describing what is available through Sannova Analytical, and the Somerset laboratory is now featured within LGM Pharma's analytical services section.

What Sannova's Existing Clients Can Expect

Continuity for the acquired company's client base was a central commitment in the announcement.

According to LGM Pharma, Sannova clients will keep their team, their methods, and their contacts after the deal. The same people who have been serving those clients remain in place, and the technical methods those clients have developed are preserved. What changes is what those clients can choose to access.

LGM Pharma positions itself as a provider of tailored API sourcing, and a Sannova client can now pair the analytical testing already conducted at the Somerset laboratory, if they choose, with LGM Pharma's upstream sourcing arm, its regulatory support, and its regulatory intelligence offering.

For a client whose relationship with the organization previously extended only to the New Jersey laboratory, the practical effect described by the company is a widened service menu spanning analytical testing, GLP bioanalysis, specialized impurity testing, and, optionally, sourcing and regulatory services.

Two Cities, One Announcement

The October 22, 2026 announcement was issued jointly from the company's two locations, Boca Raton, Fla., and Somerset, N.J., underscoring the geographic pairing of LGM Pharma's Florida headquarters with Sannova's New Jersey laboratory operations.

The pairing gives the combined organization a presence on both sides of the deal's joint dateline.

What the Source Material Covers and What It Leaves Out

The information in this article comes from LGM Pharma's own announcement and website. The company has stated what the acquisition adds, whom it affects, and what existing clients can expect. Financial terms of the deal, names of executives involved, statements about headcount, and plans for physical expansion of either facility were not part of the source material and are therefore not reported here.

What the announcement does establish is the strategic logic as LGM Pharma presents it: a company whose core business includes API sourcing, contract analytical testing, and drug development services has acquired a contract research organization whose laboratory specializes in cGMP analytical and GLP bioanalytical work, with particular strengths in genotoxic and nitrosamine impurity testing and extractables and leachables evaluations.

Existing Sannova clients continue with the same team, methods, and contacts, while gaining access to LGM Pharma's API sourcing and regulatory intelligence offerings.

The combined capabilities are now presented on the company's website under both its analytical services section and the dedicated Sannova capabilities page.